Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|OBP-801||YM753|YM-753||HDAC Inhibitor 38||OBP-801 (YM753) is a histone deacetylase inhibitor belonging to the cyclic peptide class, which may induce both cell cycle arrest and apoptosis (PMID: 18292931, PMID: 23900601, PMID: 32277670).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||urinary bladder cancer||not applicable||OBP-801||Preclinical - Cell culture||Actionable||In a preclinical study, OBP-801 treatment resulted in decreased cell viability in multiple human bladder cancer cell lines in culture (PMID: 27406983).||27406983|
|Unknown unknown||Advanced Solid Tumor||not applicable||OBP-801||Preclinical - Cell line xenograft||Actionable||In a preclinical study, OBP-201 (YM753) inhibited growth of several solid tumor cell lines in culture and demonstrated anti-tumor activity in a colon cancer cell line xenograft model (PMID: 18292931).||18292931|
|Unknown unknown||rhabdoid cancer||not applicable||OBP-801||Preclinical - Cell line xenograft||Actionable||In a preclinical study, OBP-801 treatment inhibited proliferation and induced apoptosis in rhabdoid tumor cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 32847975).||32847975|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02414516||Phase I||OBP-801||A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors||Unknown status||USA||0|